In-Hospital 30-Day Survival Among Young Adults With Coronavirus Disease 2019: A Cohort Study.
coronavirus disease 2019 (COVID-19)
mortality
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
young adults
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
11
2020
accepted:
05
05
2021
entrez:
29
6
2021
pubmed:
30
6
2021
medline:
30
6
2021
Statut:
epublish
Résumé
Our objective was to characterize young adult patients hospitalized with coronavirus disease 2019 (COVID-19) and identify predictors of survival at 30 days. This retrospective cohort study took place at 12 acute care hospitals in the New York City area. Patients aged 18-39 hospitalized with confirmed COVID-19 between March 1 and April 27, 2020 were included in the study. Demographic, clinical, and outcome data were extracted from electronic health record reports. A total of 1013 patients were included in the study (median age, 33 years; interquartile range [IQR], 28-36; 52% female). At the study end point, 940 (92.8%) patients were discharged alive, 18 (1.8%) remained hospitalized, 5 (0.5%) were transferred to another acute care facility, and 50 (4.9%) died. The most common comorbidities in hospitalized young adult patients were obesity (51.2%), diabetes mellitus (14.8%), and hypertension (13%). Multivariable analysis revealed that obesity (adjusted hazard ratio [aHR], 2.71; 95% confidence interval [CI], 1.28-5.73; Obesity was identified as the strongest negative predictor of 30-day in-hospital survival in young adults with COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Our objective was to characterize young adult patients hospitalized with coronavirus disease 2019 (COVID-19) and identify predictors of survival at 30 days.
METHODS
METHODS
This retrospective cohort study took place at 12 acute care hospitals in the New York City area. Patients aged 18-39 hospitalized with confirmed COVID-19 between March 1 and April 27, 2020 were included in the study. Demographic, clinical, and outcome data were extracted from electronic health record reports.
RESULTS
RESULTS
A total of 1013 patients were included in the study (median age, 33 years; interquartile range [IQR], 28-36; 52% female). At the study end point, 940 (92.8%) patients were discharged alive, 18 (1.8%) remained hospitalized, 5 (0.5%) were transferred to another acute care facility, and 50 (4.9%) died. The most common comorbidities in hospitalized young adult patients were obesity (51.2%), diabetes mellitus (14.8%), and hypertension (13%). Multivariable analysis revealed that obesity (adjusted hazard ratio [aHR], 2.71; 95% confidence interval [CI], 1.28-5.73;
CONCLUSIONS
CONCLUSIONS
Obesity was identified as the strongest negative predictor of 30-day in-hospital survival in young adults with COVID-19.
Identifiants
pubmed: 34183983
doi: 10.1093/ofid/ofab233
pii: ofab233
pmc: PMC8135976
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab233Subventions
Organisme : NIA NIH HHS
ID : R24 AG064191
Pays : United States
Organisme : NLM NIH HHS
ID : R01 LM012836
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA224918
Pays : United States
Organisme : ACL HHS
ID : U01OH011690
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL145114
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Influenza Other Respir Viruses. 2018 May;12(3):307-313
pubmed: 29356350
Pol Arch Intern Med. 2020 Apr 30;130(4):304-309
pubmed: 32231171
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
BMJ Open Diabetes Res Care. 2020 Apr;8(1):
pubmed: 32345579
Lancet. 2020 Apr 25;395(10233):1321-1322
pubmed: 32277876
Obesity (Silver Spring). 2020 Sep;28(9):1595-1599
pubmed: 32445512
PLoS Curr. 2014 Mar 26;6:
pubmed: 24744975
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
PLoS One. 2013 Aug 05;8(8):e69586
pubmed: 23940526
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Clin Infect Dis. 2020 Jul 28;71(15):896-897
pubmed: 32271368
Clin Infect Dis. 2020 Nov 19;71(16):2079-2088
pubmed: 32361723
Am J Med. 2005 Sep;118(9):948-56
pubmed: 16164877
JAMA Intern Med. 2020 Sep 9;:
pubmed: 32902580
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
JAMA. 2020 Aug 25;324(8):799-801
pubmed: 32702090
JAMA. 2020 Apr 14;323(14):1335
pubmed: 32181795
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
Am J Transplant. 2020 Jul;20(7):1819-1825
pubmed: 32351040
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1788-1795
pubmed: 32279081